将已构建的插入IL-24等细胞因子编码基因的溶瘤病毒，转染到体

外诱导的HIM-IC细胞内，通过特殊的基因改造，使溶瘤病毒在HIM-IC细胞

内增殖但不破坏HIM-IC细胞，然后向患者体内回输HIM-IC细胞，使融瘤病

毒特异性导向肿瘤细胞，在其内大量复制并＊终摧毁肿瘤细胞。

技术特点

l   IC细胞本身具有非MHC限制性的非特异性免疫杀伤作用，对

肿瘤细胞有杀伤活性；

l   通过IC细胞携带溶瘤病毒并释放到肿瘤细胞内，使溶瘤病毒

特异性导向肿瘤细胞，并发挥溶瘤活性；

l   插入在溶瘤病毒基因组的细胞因子基因随着病毒的扩增在肿瘤

细胞内表达，并释放细胞因子，直接发挥抗肿瘤活性；

l   IC细胞作为载体向肿瘤细胞导向溶瘤病毒，减少溶瘤病毒直

接注射被机体免疫系统的清除以及副作用；

 因此这种溶瘤病毒与HIM-IC免疫细胞的联合治疗法比单一的细胞治

疗或溶瘤病毒治疗具有更高的特异性和杀伤活性。

Oncolytic virus / CIK technology

The oncolytic virus integrated with IL-24 and other cytokine genes was transduced

 into CIK cells. The genetically modified oncolytic virus would proliferate in CIK cells 

without destroying CIK cells. The virus harbored CIK cells were then transfused to

 the patient, specifically targeting the oncolytic virus to tumor cells, and ultimately 

destroy the tumor cells.

Technical features

1.   CIK cells possess non-MHC-specific and nonspecific cytotoxicity against

 tumor cells;

2.   Oncolytic virus carried in the CIK cells would be targeted to, released into

 and then more  efficiently kill the tumor cells;

3.   The cytokine gene integrated in the genome of the oncolytic virus is expressed 

in the tumor cells along with the expansion of the virus, which directly develop the

 antitumor activity.

4.   Using CIK cell as carrier of oncolytic virus helps to reduce the clearence of virus 

by receptorimmune system and otherwise some side effects caused by naked

 virus injection  Therefore, the combination of the oncolytic virus and CIK immune

 cells has a higher specificity and killing activity than CIK or oncolytic virus alone.